Panacea Biotec Limited (NSE: PANACEABIO, BSE: 531349) became one of India’s standout movers on Friday, December 26, 2025, after the company disclosed a meaningful upgrade to its UNICEF vaccine supply award—an update that immediately lit up the stock tape even as the broader market drifted in thin year-end trade. 1
By midday, Panacea Biotec’s share price was sharply higher and trading at levels not seen in weeks, supported by heavy volumes and a surge in traded value. The catalyst wasn’t vague “sentiment” or rumor—it was a concrete, exchange-filed change in contracted order values for a WHO pre-qualified pentavalent vaccine (Easyfive‑TT®), which materially improves revenue visibility for calendar years 2026 and 2027. 2
What follows is a complete, publication-ready round-up of the current news, market reaction, and the most widely referenced forecasts/technical reads circulating on 26.12.2025—with context on fundamentals and the risks that still matter.
What happened on 26 December 2025: Panacea Biotec stock jumps on UNICEF award amendment
Panacea Biotec disclosed that UNICEF amended its existing award relating to supplies of the company’s WHO pre-qualified fully liquid pentavalent vaccine, Easyfive‑TT® (DTwP‑HepB‑Hib), under a multi-year supply framework covering calendar years 2023–2027. 2
The key numbers that moved the stock
According to Panacea Biotec’s December 24, 2025 stock-exchange disclosure, the UNICEF award amendment includes:
- CY2026: contract value increased by US$ 2.55 million (≈ ₹23 crore) from US$ 14.25 million to US$ 16.8 million
- CY2027: contract value increased by US$ 2.70 million (≈ ₹24 crore) from US$ 12.48 million to US$ 15.18 million
- CY2027 (additional): an additional award worth ~US$ 3.68 million (≈ ₹33 crore) 2
Put together, the incremental uplift across the two years is US$ 8.93 million (roughly ₹80 crore, using the company’s rupee approximations). 3
Why investors reacted quickly
UNICEF-linked vaccine awards are often interpreted by markets as “quality + continuity” signals—because UNICEF procurement typically demands strict compliance, documentation discipline, and consistent manufacturing capability. On the day, the revised award was treated as a visibility upgrade: more contracted value already inside the tent for 2026–27, rather than speculative future wins. 1
Panacea Biotec share price today: price action, day range, volume and market cap
Panacea Biotec’s stock move was loud enough to show up in broader market coverage: Reuters noted Indian benchmarks were subdued in holiday-thinned trade, while Panacea Biotec surged sharply on the UNICEF contract news. 4
Intraday snapshot (26 Dec 2025)
Market data published during the session showed:
- Previous close: ₹359.15
- Open: ₹373.00
- Day’s range:₹366.10 to ₹419.40
- Volume: ~12,998,778 shares (as captured midday)
- VWAP: ~₹408.56
- Market cap: ~₹2,527 crore (intraday figure) 5
Business Standard reported the stock rising nearly 14% and touching ₹409.25 intraday (its “highest level since November 13,” per that report), with strong turnover on the NSE. 1
52-week context
Panacea Biotec has been volatile over the last year, with widely-circulated figures showing:
- 52-week high: about ₹581.90 (April 30, 2025)
- 52-week low: about ₹281.10 (February 28, 2025) 1
This matters because a 14–16% single-session spike can look like “a breakout,” but it’s happening inside a wider 52-week range where the stock previously traded far higher—meaning many holders may still be sitting on overhead supply from earlier peaks.
What the UNICEF contract upgrade actually means: revenue visibility, timing, and execution reality
A useful mental model: award value uplift is not the same thing as immediate revenue. The company’s disclosure and market coverage emphasize that execution is tied to orders and delivery schedules.
Capital Market’s coverage noted the international supply contract will be executed “as per orders received from UNICEF” during CY2026 and CY2027, and that UNICEF is expected to publish award details on its official channels. 3
Why “calendar year” timing is important
Many Indian listed companies report financials on a fiscal year basis (FY). UNICEF’s referenced supply periods in this case are calendar years, which means investors often have to translate “CY2026/CY2027” into how it flows into FY26/FY27/FY28 reporting windows, depending on shipment timing, billing terms, and revenue recognition policies. That translation step is where expectations can get messy.
Governance and related-party angle
Market coverage stated Panacea Biotec indicated the award does not involve promoter or promoter group interest. 3
Recent corporate developments: CFO resignation and leadership changes in December 2025
For investors tracking governance continuity (especially in pharma/biotech, where compliance matters), Panacea Biotec also had meaningful management updates in December:
- The company disclosed that Devender Gupta resigned and his last working day would be December 15, 2025. 6
- The Board approved the appointment of Vinod Goel as Chief Financial Officer, effective December 16, 2025, following the cessation of the prior CFO. 7
- The company also disclosed that Ankit Jain was appointed Company Secretary and Compliance Officer, effective December 16, 2025. 7
While these leadership changes did not drive the 26 Dec spike as directly as the UNICEF award amendment, they provide context for investors who care about internal controls, disclosure discipline, and execution capability—especially when large international supply relationships are involved.
Latest financial performance: what the most recent quarterly results show
A stock can jump on a contract headline and still be working through profitability issues underneath. Panacea Biotec’s most recent reported quarter (ended September 2025) showed losses.
Standalone performance (quarter ended Sep 2025)
Reported coverage of standalone results indicated:
- Net sales:₹90.81 crore (up 18.49% YoY)
- Net loss:₹15.64 crore (vs profit in the year-ago quarter, per the same report) 8
Consolidated performance (quarter ended Sep 2025)
Reported consolidated numbers showed:
- Net sales:₹141.13 crore (down 4.22% YoY)
- Net loss:₹13.92 crore (vs profit in the year-ago quarter) 9
This is the “two truths” setup markets love: improving business visibility via global tenders on one hand, but recent losses on the other. Bulls typically argue contracts and volumes eventually fix margins; bears argue pricing pressure and costs can keep profits elusive even with deals.
Forecasts and analyses for PANACEABIO on 26.12.2025: what the market tools are saying
Here’s the honest state of play on December 26, 2025: for Panacea Biotec, traditional sell-side consensus forecasts are limited or absent on many mainstream retail platforms, so “forecasts” often mean technical indicators or model-driven projections, not a deep coverage universe of analyst price targets.
Analyst coverage and consensus: thin on many platforms
- Moneycontrol’s “Forecast” area for Panacea Biotec showed no share price forecast data and no analyst rating data at the time of capture. 5
- Simply Wall St stated that Panacea Biotec has no analyst forecast, and that future earnings can’t be reliably calculated there due to limitations in available past data/coverage on that platform. 10
- Alpha Spread also noted the stock doesn’t have price targets made by Wall Street professionals on its system. 11
Interpretation: If you’re looking for a clean “consensus target price” story, Panacea Biotec is not behaving like a mega-cap with 20 analysts publishing quarterly models. Most public commentary instead leans on price action, tenders/orders, and chart-based tools.
Technical sentiment: mixed, depending on the tool and timestamp
- Moneycontrol’s technical panel displayed a “VERY BULLISH” trend label (timeframe selections like daily/weekly/monthly were visible). 5
- TipRanks technical indicators (timestamped Dec 26, 2025, 02:35 AM) showed a Neutral RSI (48.66), MACD marked as Sell (-7.27), and ADX marked as Buy (19.22)—a blend of signals rather than a single-direction “all clear.” 12
Interpretation: After a big gap-and-run move, it’s common for technical dashboards to disagree—some are trend-following (they flip bullish quickly), others are momentum/oscillator-based (they can stay neutral or even flash “sell” if the move is sharp and the indicator lags).
“Forecast” models: treat as opinionated math, not gospel
Some websites publish algorithmic price forecasts. These can be interesting as a sentiment artifact (what retail tools are showing), but they are not the same as a researched analyst model with management calls and channel checks.
If you include them at all in an investment narrative, the responsible framing is: model output, highly assumption-sensitive, not a substitute for fundamentals.
Why Panacea Biotec stock is in focus: the bigger story behind recurring global vaccine awards
Panacea Biotec is frequently discussed in the context of global institutional procurement because it supplies vaccines that can qualify for large-scale tenders. Market coverage on December 26 tied the move directly to the WHO-prequalified pentavalent product and UNICEF procurement. 13
From a business-model lens, this creates a distinctive profile:
- Upside lever: Large tender wins can scale volumes quickly and create multi-year revenue visibility.
- Constraint: Tender business can be price-competitive; margin outcomes depend on cost discipline, yields, forex, and execution quality.
This is why the December 26 reaction matters: the market wasn’t just celebrating “a new deal,” but a tangible increase in contracted value inside an ongoing relationship.
Risks to watch after the 26 Dec surge
Even with an upbeat contract headline, investors typically track a few practical risks in vaccine-tender-driven names:
- Execution risk (deliveries, timelines, quality): large buyers can be unforgiving on compliance and scheduling.
- Margin and working-capital dynamics: scale doesn’t always equal profitability if pricing is tight or costs rise.
- Forex sensitivity: contracts priced in USD vs costs in INR can help or hurt depending on currency moves.
- Headline-driven volatility: stocks that move 10–15% on news can retrace quickly if the next data point disappoints.
None of these invalidate the UNICEF award uplift—but they explain why the next pieces of information (order schedules, shipment execution, quarterly margin trajectory) matter as much as the headline itself.
What to track next for Panacea Biotec (PANACEABIO) after 26 December 2025
Based on what was disclosed and reported around the move, the next catalysts investors will likely watch include:
- Further detail/confirmation as UNICEF publishes procurement award information (as referenced in market coverage). 3
- Subsequent quarterly results to see whether higher contracted visibility translates into improved operating leverage (especially given the latest reported losses). 9
- Any additional global tender wins or amendments, which can act as repeat catalysts in this business model.
